Recent Advances in the Study of the Immune Escape Mechanism of SFTSV and Its Therapeutic Agents

Lei Chen; Tingting Chen; Ruidong Li; Yingshu Xu; Yongai Xiong

doi:10.3390/v15040940

Recent Advances in the Study of the Immune Escape Mechanism of SFTSV and Its Therapeutic Agents

Viruses. 2023 Apr 10;15(4):940. doi: 10.3390/v15040940.

Authors

Lei Chen^{1

2}, Tingting Chen^{1

2}, Ruidong Li^{1

2}, Yingshu Xu^{1

2}, Yongai Xiong^{1

2}

Affiliations

¹ Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563000, China.
² Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563000, China.

Abstract

Sever fever with thrombocytopenia syndrome (SFTS) is a new infectious disease that has emerged in recent years and is widely distributed, highly contagious, and lethal, with a mortality rate of up to 30%, especially in people with immune system deficiencies and elderly patients. SFTS is an insidious, negative-stranded RNA virus that has a major public health impact worldwide. The development of a vaccine and the hunt for potent therapeutic drugs are crucial to the prevention and treatment of Bunyavirus infection because there is no particular treatment for SFTS. In this respect, investigating the mechanics of SFTS-host cell interactions is crucial for creating antiviral medications. In the present paper, we summarized the mechanism of interaction between SFTS and pattern recognition receptors, endogenous antiviral factors, inflammatory factors, and immune cells. Furthermore, we summarized the current therapeutic drugs used for SFTS treatment, aiming to provide a theoretical basis for the development of targets and drugs against SFTS.

Keywords: SFTS; immune escape; mechanism; pattern recognition receptors; therapeutic agents.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
Bunyaviridae Infections* / drug therapy
Humans
Phlebovirus*
Severe Fever with Thrombocytopenia Syndrome* / drug therapy
Thrombocytopenia* / drug therapy

Substances

Antiviral Agents

Grants and funding

This work was supported by the National Natural Science Foundation of China (NO. 82260723) and the Science and Technology Support Program of Guizhou province (NO. [2021]Genaral410).